UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): March 1, 2005



                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)


          Florida                          0-27937              65-0142474
          -------                          -------              ----------
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
           Incorporation)                                    Identification No.)

  1055 Hastings Street, Suite 1900
     Vancouver, British Columbia                                     V6E 2E9
    ----------------------------                                     -------
        (Address of Principal Executive Offices)                   (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Section 9 - Financial Statements and Exhibits
            ---------------------------------

     The Registrant is filing  certain  agreements  previously  entered into and
that are part of the Registrant's and Oriental Wave Holding Limited's business.


   Item 9.01   Financial Statements and Exhibits

      (c)   Exhibits

       Exhibit No.  Exhibit Description
       ----------   -------------------

         10.18*     Collaboration  Agreement  among  Transworld  Pharmaceuticals
                    Corporation   Inc.,   Toray   Trading   Corp.   and   Dragon
                    Pharmaceutical Inc., effective as of April 30, 2001.

         10.19*     Agent Agreement among Allwin Biotrade, Inc., Jiangsu Wuzhong
                    Industry  Co. Ltd.  and Jiangsu  Wuzhong  Industry  Co. Ltd.
                    Suzhou Zhongkai  Bio-Pharmaceuticals  Plant, effective as of
                    March 12, 2004.

         10.20*     Development  and  Manufacturing   Agreement  between  Dragon
                    Pharmaceutical Inc. and Polymun Scientific  Immunbiologische
                    Forschung GmbH, effective as of October 31, 2003.

         10.21*     Agreement  for  Advance  and Long Term Supply of Products by
                    and between  Aurobindo  (Datong)  Bio-Pharma  Co.  Ltd.  and
                    Shanxi  Weiqida  Pharmaceutical  Co.  Ltd.,  dated March 25,
                    2004.

         10.22*     Technology   Transfer   Agreement   between  Shanxi  Weiqida
                    Pharmaceutical   Co.  Ltd  and  Alpha  Process  Trust  Reg.,
                    effective as of August 6, 2002.

         10.23*     Manufacturing    Agreement   for   Dry-freeze   Levofloxacin
                    Injectable by and between Shanxi Weiqida Pharmaceutical Co.,
                    Ltd. and Shanxi Pude Pharmaceutical Co., Ltd.,  effective as
                    of April 21, 2003.

         10.24*     Technology   Transfer   Agreement   between  Shanxi  Weiqida
                    Pharmaceutical   Co.  Ltd  and  Alpha  Process  Trust  Reg.,
                    effective as of April 18, 2002.

  *  Confidential treatment requested as to certain portions, which portions are
     omitted and filed separately with the Securities and Exchange Commission.

<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  March 1, 2005                          DRAGON PHARMACEUTICAL INC.
      -------------------

                                              /s/ Maggie Deng
                                              ---------------------------------
                                              Maggie Deng
                                              Chief Operating Officer
[{"type": "8-K", "sequence": "1", "filename": "for8k.txt", "description": "FORM8K0205", "secsgml_size_bytes": 4840}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05653740"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): March 1, 2005

                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)

          Florida                          0-27937              65-0142474
          -------                          -------              ----------
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
           Incorporation)                                    Identification No.)

  1055 Hastings Street, Suite 1900
     Vancouver, British Columbia                                     V6E 2E9
    ----------------------------                                     -------
        (Address of Principal Executive Offices)                   (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 9 - Financial Statements and Exhibits
            ---------------------------------

     The Registrant is filing  certain  agreements  previously  entered into and
that are part of the Registrant's and Oriental Wave Holding Limited's business.

   Item 9.01   Financial Statements and Exhibits

      (c)   Exhibits

       Exhibit No.  Exhibit Description
       ----------   -------------------

         10.18*     Collaboration  Agreement  among  Transworld  Pharmaceuticals
                    Corporation   Inc.,   Toray   Trading   Corp.   and   Dragon
                    Pharmaceutical Inc., effective as of April 30, 2001.

         10.19*     Agent Agreement among Allwin Biotrade, Inc., Jiangsu Wuzhong
                    Industry  Co. Ltd.  and Jiangsu  Wuzhong  Industry  Co. Ltd.
                    Suzhou Zhongkai  Bio-Pharmaceuticals  Plant, effective as of
                    March 12, 2004.

         10.20*     Development  and  Manufacturing   Agreement  between  Dragon
                    Pharmaceutical Inc. and Polymun Scientific  Immunbiologische
                    Forschung GmbH, effective as of October 31, 2003.

         10.21*     Agreement  for  Advance  and Long Term Supply of Products by
                    and between  Aurobindo  (Datong)  Bio-Pharma  Co.  Ltd.  and
                    Shanxi  Weiqida  Pharmaceutical  Co.  Ltd.,  dated March 25,
                    2004.

         10.22*     Technology   Transfer   Agreement   between  Shanxi  Weiqida
                    Pharmaceutical   Co.  Ltd  and  Alpha  Process  Trust  Reg.,
                    effective as of August 6, 2002.

         10.23*     Manufacturing    Agreement   for   Dry-freeze   Levofloxacin
                    Injectable by and between Shanxi Weiqida Pharmaceutical Co.,
                    Ltd. and Shanxi Pude Pharmaceutical Co., Ltd.,  effective as
                    of April 21, 2003.

         10.24*     Technology   Transfer   Agreement   between  Shanxi  Weiqida
                    Pharmaceutical   Co.  Ltd  and  Alpha  Process  Trust  Reg.,
                    effective as of April 18, 2002.

  *  Confidential treatment requested as to certain portions, which portions are
     omitted and filed separately with the Securities and Exchange Commission.
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  March 1, 2005                          DRAGON PHARMACEUTICAL INC.
      -------------------

                                              /s/ Maggie Deng
                                              ---------------------------------
                                              Maggie Deng
                                              Chief Operating Officer